Randomised placebo-controlled trials are the gold standard to assess novel drugs in ulcerative colitis and Crohn's disease. However, there might be risks associated with receiving placebo. We aimed to examine the harms associated with receiving placebo in trials of licensed biologics and small molecules for the induction of remission in ulcerative colitis and luminal Crohn's disease in a meta-analysis.

中文翻译：

---

在生物疗法和小分子作为炎症性肠病诱导疗法的试验中，安慰剂的危害：系统评价和荟萃分析


随机安慰剂对照试验是评估溃疡性结肠炎和克罗恩病新药的金标准。然而，接受安慰剂可能存在风险。我们旨在在一项荟萃分析中检查在获得许可的生物制剂和小分子药物诱导溃疡性结肠炎和管腔性克罗恩病缓解的试验中接受安慰剂的相关危害。